2012 03 v.47 323-326
抑郁症发病机制研究进展
基金项目(Foundation):
国家自然科学基金(编号:309400434)
邮箱(Email):
DOI:
10.19405/j.cnki.issn1000-1492.2012.03.025
中文作者单位:
第二军医大学基础医学部生理学教研室;
摘要(Abstract):
抑郁症是由多种因素引起的情感障碍性疾病,其发病机制目前尚未完全阐明。现从炎症反应学说、单胺类神经递质及其受体学说、下丘脑-垂体-肾上腺(HPA)轴功能失调学说、神经营养因子学说以及多因素综合作用共5个方面总结其发病机制。
关键词(KeyWords):
抑郁症;;单胺类神经递质;;HPA轴;;神经营养因子;;炎症反应
| 5,565 | 162 | 131 |
| 下载次数 | 被引频次 | 阅读次数 |
参考文献
[1]Maes M,Vandoolaeghe E,Ranjan R,et al.Increased serum inter-leukin-1-receptor-antagonist concentrations in major depression[J].J Affect Disord,1995,36(1-2):29-36.
[2]Catena-Dell'Osso M,Bellantuono C,Consoli G,et al.Inflammatoryand neurodegenerative pathways in depression:a new avenue forantidepressant development?[J].Curr Med Chem,2011,18(2):245-55.
[3]Tsao C W,Lin Y S,Chen C C,et al.Cytokines and serotonintransporter in patients with major depression[J].Prog Neuropsy-chopharmacol Biol Psychiatry,2006,30(5):899-905.
[4]Kassed C A,Herkenham M.NF-kappaB p50-deficient mice showreduced anxiety-like behaviors in tests of exploratory drive and anx-iety[J].Behav Brain Res,2004,154(2):577-84.
[5]Constant A,Castera L,Dantzer R,et al.Mood alterations during in-terferon-alfa therapy in patients with chronic hepatitis C:evidencefor an overlap between manic/hypomanic and depressive symptoms[J].J Clin Psychiatry,2005,66(8):1050-7.
[6]Benrick A,Schéle E,Pinnock S B,et al.Interleukin-6 geneknockout influences energy balance regulating peptides in the hy-pothalamic paraventricular and supraoptic nuclei[J].J Neuroen-docrinol,2009,21(7):620-8.
[7]Wichers M C,Maes M.The role of indoleamine 2,3-dioxygenase(IDO)in the Pathophysiology of interferon-alpha-induced depres-sion[J].J Psychiatry Neurosci,2004,29(1):11-7.
[8]Pariante C M,Pearce B D,Pisell T L,et al.The proinflammatorycytokine,interleukin-1alpha,reduces glucocorticoid receptor trans-location and function[J].Endocrinology,1999,140(9):4359-66.
[9]Maes M,Leonard B E,Myint A M,et al.The new‘5-HT’hypothe-sis of depression:cell-mediated immune activation induces in-doleamine 2,3-dioxygenase,which leads to lower plasma trypto-phan and an increased synthesis of detrimental tryptophan catabo-lites(TRYCATs),both of which contribute to the onset of depres-sion[J].Prog Neuropsychopharmacol Biol Psychiatry,2011,35(3):702-21.
[10]Han Y,Khodr C E,Sapru M K,et al.A microRNA embeddedAVV alpha-synuclein gene silencing vector for dopaminergic neu-rons[J].Brain Res,2011,1386:15-24.
[11]Berton O,Nestler E J.New approaches to antidepressant drug dis-covery:beyond monoamines[J].Nat Rev Neurosci,2006,7(2):137-51.
[12]Mackowiak M,Czyrak A,Wedzony K.The involvement of 5-HT1aserotonin receptors in the pathophysio1ogy and pharmacotherapy ofschizophrenia[J].Psychiatr Pol,2000,34(4):607-21.
[13]Lopez-Figuera A L,Norton C S,Lopez-Figuera M O,et al.Seroto-nin 5-HT1A,5-HT1B,and 5-HT2A receptor mRNA expression insubjects with major depression,bipolar disorder,and schizophrenia[J].Biol Psychiatry,2004,55(3):225-33.
[14]León-Ponte M,Ahern G P,O’Connell P J.Serotonin provides anaccessory signal to enhance T-cell activation by signaling throughthe 5-HT7 receptor[J].Blood,2007,109(8):3139-46.
[15]Catalán R,Gallart J M,Castellanos J M,et al.Plasma corticotrop-in-releasing factor in depressive disorders[J].Biol Psychiatry,1998,44(1):15-20.
[16]Binder E B,Salyaklna D,Lichtner P,et al.Polymorphisms in FK-BP5 are associated with increased recurrence of depressive epi-sodes and rapid response to antidepressnat treatment[J].Nat Gen-et,2004,36(12):1319-25.
[17]Frisch P,Bilkei-GorzóA,Rácz I,et al.Modulation of the CRHsystem by substance P/NKA in an animal model of depression[J].Behav Brain Res,2010,213(1):103-8.
[18]Catalan R,Gallart J M,Caslellanos J M,et al.Plasma corticotrop-in-releasing factor in depressive disorders[J].Biol Psychiatry,1998,44(1):15-20.
[19]Duman R S,Monteggia L M.A neurotrophic model for stress-relat-ed mood disorders[J].Biol Psychiatry,2006,59(12):1116-27.
[20]Eisch A J,Bolanos C A,Dewit J,et al.Brain-derived neurotrophicfactor in the ventral midbrain-nucleus accumbens pathway:a rolein depression[J].Biol Psychiatry,2003,54(10):994-1005.
[21]Capuron L,Ravaud A,Neveu P J,et al.Association between de-creased serum tryptophan concentrations and depressive symptomsin cancer patients undergoing cytokine therapy[J].Mol Psychia-try,2002,7(5):468-73.
[22]Wichers M,Maes M.The role of indoleamine 2,3-dioxygenase(IDO)in the pathophysiology of interferon-alpha-induced depres-sion[J].J Psychiatry Neurosci,2004,29(1):11-7.
[23]Varfolomeev E E,Ashkenazi A.Tumor necrosis factor:an apopto-sis JuNKie[J].Cell,2004,116(4):491-7.
[2]Catena-Dell'Osso M,Bellantuono C,Consoli G,et al.Inflammatoryand neurodegenerative pathways in depression:a new avenue forantidepressant development?[J].Curr Med Chem,2011,18(2):245-55.
[3]Tsao C W,Lin Y S,Chen C C,et al.Cytokines and serotonintransporter in patients with major depression[J].Prog Neuropsy-chopharmacol Biol Psychiatry,2006,30(5):899-905.
[4]Kassed C A,Herkenham M.NF-kappaB p50-deficient mice showreduced anxiety-like behaviors in tests of exploratory drive and anx-iety[J].Behav Brain Res,2004,154(2):577-84.
[5]Constant A,Castera L,Dantzer R,et al.Mood alterations during in-terferon-alfa therapy in patients with chronic hepatitis C:evidencefor an overlap between manic/hypomanic and depressive symptoms[J].J Clin Psychiatry,2005,66(8):1050-7.
[6]Benrick A,Schéle E,Pinnock S B,et al.Interleukin-6 geneknockout influences energy balance regulating peptides in the hy-pothalamic paraventricular and supraoptic nuclei[J].J Neuroen-docrinol,2009,21(7):620-8.
[7]Wichers M C,Maes M.The role of indoleamine 2,3-dioxygenase(IDO)in the Pathophysiology of interferon-alpha-induced depres-sion[J].J Psychiatry Neurosci,2004,29(1):11-7.
[8]Pariante C M,Pearce B D,Pisell T L,et al.The proinflammatorycytokine,interleukin-1alpha,reduces glucocorticoid receptor trans-location and function[J].Endocrinology,1999,140(9):4359-66.
[9]Maes M,Leonard B E,Myint A M,et al.The new‘5-HT’hypothe-sis of depression:cell-mediated immune activation induces in-doleamine 2,3-dioxygenase,which leads to lower plasma trypto-phan and an increased synthesis of detrimental tryptophan catabo-lites(TRYCATs),both of which contribute to the onset of depres-sion[J].Prog Neuropsychopharmacol Biol Psychiatry,2011,35(3):702-21.
[10]Han Y,Khodr C E,Sapru M K,et al.A microRNA embeddedAVV alpha-synuclein gene silencing vector for dopaminergic neu-rons[J].Brain Res,2011,1386:15-24.
[11]Berton O,Nestler E J.New approaches to antidepressant drug dis-covery:beyond monoamines[J].Nat Rev Neurosci,2006,7(2):137-51.
[12]Mackowiak M,Czyrak A,Wedzony K.The involvement of 5-HT1aserotonin receptors in the pathophysio1ogy and pharmacotherapy ofschizophrenia[J].Psychiatr Pol,2000,34(4):607-21.
[13]Lopez-Figuera A L,Norton C S,Lopez-Figuera M O,et al.Seroto-nin 5-HT1A,5-HT1B,and 5-HT2A receptor mRNA expression insubjects with major depression,bipolar disorder,and schizophrenia[J].Biol Psychiatry,2004,55(3):225-33.
[14]León-Ponte M,Ahern G P,O’Connell P J.Serotonin provides anaccessory signal to enhance T-cell activation by signaling throughthe 5-HT7 receptor[J].Blood,2007,109(8):3139-46.
[15]Catalán R,Gallart J M,Castellanos J M,et al.Plasma corticotrop-in-releasing factor in depressive disorders[J].Biol Psychiatry,1998,44(1):15-20.
[16]Binder E B,Salyaklna D,Lichtner P,et al.Polymorphisms in FK-BP5 are associated with increased recurrence of depressive epi-sodes and rapid response to antidepressnat treatment[J].Nat Gen-et,2004,36(12):1319-25.
[17]Frisch P,Bilkei-GorzóA,Rácz I,et al.Modulation of the CRHsystem by substance P/NKA in an animal model of depression[J].Behav Brain Res,2010,213(1):103-8.
[18]Catalan R,Gallart J M,Caslellanos J M,et al.Plasma corticotrop-in-releasing factor in depressive disorders[J].Biol Psychiatry,1998,44(1):15-20.
[19]Duman R S,Monteggia L M.A neurotrophic model for stress-relat-ed mood disorders[J].Biol Psychiatry,2006,59(12):1116-27.
[20]Eisch A J,Bolanos C A,Dewit J,et al.Brain-derived neurotrophicfactor in the ventral midbrain-nucleus accumbens pathway:a rolein depression[J].Biol Psychiatry,2003,54(10):994-1005.
[21]Capuron L,Ravaud A,Neveu P J,et al.Association between de-creased serum tryptophan concentrations and depressive symptomsin cancer patients undergoing cytokine therapy[J].Mol Psychia-try,2002,7(5):468-73.
[22]Wichers M,Maes M.The role of indoleamine 2,3-dioxygenase(IDO)in the pathophysiology of interferon-alpha-induced depres-sion[J].J Psychiatry Neurosci,2004,29(1):11-7.
[23]Varfolomeev E E,Ashkenazi A.Tumor necrosis factor:an apopto-sis JuNKie[J].Cell,2004,116(4):491-7.
基本信息:
DOI：10.19405/j.cnki.issn1000-1492.2012.03.025
中图分类号:R749.4
引用信息:
[1]徐永君,盛慧,倪鑫.抑郁症发病机制研究进展[J].安徽医科大学学报,2012,47(03):323-326.DOI:10.19405/j.cnki.issn1000-1492.2012.03.025.
基金信息:
国家自然科学基金(编号:309400434)